Kintara Therapeutics, Inc. announced that on April 29, 2021, Tamara A. Seymour was appointed to the Board of Directors of the Company. In connection with Ms. Seymour’s appointment, John Liatos submitted his resignation from the Board, effective as of April 29, 2021. Mr. Liatos’s resignation was not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. Mr. Liatos will continue in his role as Senior Vice President of Business Development of the Company. Ms. Seymour has served as a member of the board of directors and audit committee of Artelo Biosciences, Inc., since March 2021. Previously, she served as a member of the board of directors and Chair of the audit committee of Beacon Discovery, Inc., from September 2018 until its acquisition by Eurofins Scientific in March 2021. Ms. Seymour served as Interim Chief Financial Officer of Immunic, Inc. from April 2019 to August 2019. She was Chief Financial Officer of Signal Genetics, Inc, from August 2014 to February 2017. Ms. Seymour will serve as a director on the Board until the 2021 annual meeting of the Company’s stockholders or until her successor is elected and qualified, subject to her earlier resignation or removal.